Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y7WL
|
|||
| Former ID |
DNC000889
|
|||
| Drug Name |
Lorglumide
|
|||
| Synonyms |
Lorglumide; 97964-56-2; Lorglumide [INN]; Lorglumidum [Latin]; Lorglumida [Spanish]; CR-1409; CCRIS 6857; CHEMBL24938; CHEBI:88307; CR 1409; D,L-4-(3,4-Dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pentanoic acid; Lorglumida; Lorglumidum; (+-)-4-(3,4-Dichlorobenzamido)-N,N-dipentylglutaramic acid; 4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid; Pentanoic acid, 4-((3,4-dichlorobenzoyl)amino)-5-(dipentylamino)-5-oxo-, (+-)-; C22H32Cl2N2O4; 4-((3,4-dichlorobenzoyl)amino)-5-(dipentylamino)-5-oxopentanoic a
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pancreatic malfunction [ICD-11: DC30-DC3Z] | Terminated | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H32Cl2N2O4
|
|||
| Canonical SMILES |
CCCCCN(CCCCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl
|
|||
| InChI |
1S/C22H32Cl2N2O4/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28)
|
|||
| InChIKey |
IEKOTSCYBBDIJC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 97964-56-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7979802, 8152486, 11364522, 11367084, 11369646, 11377808, 11466943, 11468063, 11486715, 11495442, 12013646, 14858075, 29223074, 47291331, 47291332, 47589196, 47959979, 48110682, 48334727, 48334728, 50002818, 50143136, 57322069, 85209144, 85787321, 92309296, 103190039, 103839677, 103856371, 103921383, 104305024, 117462169, 128156102, 134340189, 135025885, 135650531, 137142843, 176484400, 179039128, 184548356, 226514992, 241169171
|
|||
| ChEBI ID |
CHEBI:88307
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cholecystokinin receptor type A (CCKAR) | Target Info | Antagonist | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Insulin secretion | ||||
| Pancreatic secretion | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 891). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000580) | |||
| REF 3 | Behavioral and neurochemical study on the role of the brain cholecystokinin system in anxiety. Hokkaido Igaku Zasshi. 1998 Sep;73(5):463-73. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.